Predicting Success in the Biotech and Pharma Sectors Mark Schoenebaum of ISI Group earned two top spots on this year's All-America Research Team. Here he explains how he differentiates the good stocks from the bad. Related Articles Premium Updated: The Impact of Low Prices in Today’s Market: Opportunities and Challenges Ailene Barona China’s Sluggish M&A Market Will Likely Stay Slow in 2022 John Crabb Listicle - 7 Smart Investments to Grow Your Wealth in 2025 Sponsored by Northern Trust